Silence Therapeutics plc

Report Publication Announcement • Mar 22, 2016

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 8232S

Silence Therapeutics PLC

22 March 2016

 

Notice of Results

22 March 2016

Silence Therapeutics plc

Silence Therapeutics plc, AIM: SLN, a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, will announce results for the year to 31 December 2015 and trading outlook on Tuesday 5 April.

The statement will include full details on the Atu027 Phase 2a clinical results in pancreatic cancer. There will also be a detailed update on other pipeline projects, technology, IP and patent developments.

Enquiries:

Silence Therapeutics plc Ali Mortazavi, Chief Executive Officer Timothy Freeborn, Chief Financial Officer	Tel:  +44 (0)20 3457 6900
Canaccord Genuity Limited (Nominated Adviser and Joint Broker) Dr Julian Feneley/Henry Fitzgerald-O'Connor/Emma Gabriel	Tel:  +44 (0)20 7523 8350
Peel Hunt LLP (Joint Broker) James Steel/Dr Tom Burt/Oliver Jackson	Tel:  +44 (0)20 7418 8900
Media Enquiries: FTI Consulting Simon Conway/Brett Pollard/Stephanie Cuthbert	Tel: +44 (0) 20 3727 1000

Notes to Editors

About Silence Therapeutics plc

Our technology harnesses the body's natural mechanisms to create therapeutic effects within its own cells.  This technology can selectively silence or replace any gene in the genome, modulating gene expression up as well as down in a variety of organs and cell types, in vivo.

We have developed proprietary modifications to improve the robustness of RNA sequences, together with advanced liposomal chemistries to enhance the delivery of therapeutics. This allows the development of therapeutics for diseases with high unmet medical need. In 2015 Silence announced interim results from a Phase 2a pancreatic cancer trial using its compound, Atu027, in combination with gemcitabine.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NORDMGZFMMLGVZZ